# CureApp

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cureapp

- Industry: Healthcare IT
- Headquarters: Tokyo, Japan
- Website: www.cureapp.co.jp
- Total disclosed funding: $54M
- Latest round: Series F (Mar 12, 2021)
- Investors on record: 20

## About

CureApp, Inc. is a Japan-based medical technology company that develops digital therapeutics, enhancing treatment options for patients with various health conditions through innovative applications.CureApp, Inc., founded in 2014 and headquartered in Tokyo, Japan, is focused on developing digital therapeutics that offer alternative treatment options. The company has successfully completed 8 funding deals, with its most recent being a Series G round in August 2022, raising JPY 7.0 billion from Carlyle Group, which marks the total amount raised to JPY 7.0 billion. The company’s founder, Kohta Satake, has played a pivotal role in its establishment and growth.CureApp specializes in developing innovative digital therapeutics, primarily through their flagship product, the treatment app, which leverages medical evidence to address conditions inadequately managed by traditional pharmaceuticals and hardware medical devices. These apps aim to facilitate new treatment interventions during non-clinical hours, such as at home or while out, enabling patients to receive personalized support through the app interface. The company targets various health conditions, including nicotine dependence and non-alcoholic steatohepatitis (NASH), with its products being utilized in both clinical settings and corporate health initiatives. CureApp's solutions are designed to enhance health outcomes by promoting behavioral change and encouraging adherence to treatment protocols among users. The geographical markets for CureApp's products include Japan, where they have been integrated into local healthcare initiatives and corporate wellness programs.CureApp's revenue model is primarily based on partnerships and B2B transactions, particularly with healthcare institutions and corporate wellness programs. Their apps are structured to provide subscription-based access for users, facilitating ongoing treatment and support. For instance, their complete online smoking cessation program, "ascure," is part of various health initiatives in Japan, indicating a strategic approach to integrating their solutions into broader health systems. While specific pricing plans are not disclosed, the company’s offerings are built around tailored solutions for healthcare providers, demonstrating their commitment to delivering value to both patients and institutions. The revenue is generated through contracted agreements with health insurance organizations and corporate clients seeking to improve health outcomes for their employees through digital therapeutic interventions.Following their Series G financing in August 2022, where they raised JPY 7.0 billion, CureApp plans to invest these funds into the development of new digital therapeutics products and services. The company is also looking to expand its market presence beyond Japan, targeting new geographic regions to reach more patients in need of innovative therapeutic options. Specific expansion timelines and new product launch dates have yet to be disclosed, but the company is actively working towards enhancing its offerings to further support patient care.

## Funding rounds

- Series F, Mar 12, 2021, $15M — Dai-ichi Life Insurance, Sumitomo Mitsui Trust Investment, ITOCHU Technology Ventures, SMBC Venture Capital, Koshidaka Holdings, Healthcare Innovation, Saisei Ventures, Shinsei Impact Investment
- Series E, Jul 5, 2019, $21M — Dai-ichi Life Insurance, ITOCHU Technology Ventures, Mizuho Capital, Mori Trust, Keio Innovation Initiative, Iwagin Jigyo Souzou Capital, Koshidaka Holdings, INTAGE HOLDINGS Inc.
- Series D, Feb 26, 2018, $14M — Dai-ichi Life Insurance, Itochu, Mitsubishi UFJ Capital, ITOCHU Technology Ventures, Mizuho Capital, SBI Investment, Chibagin Capital, Cyberdyne, Inc., Beyond Next Ventures, Keio Innovation Initiative, Saison Ventures, Iwagin Jigyo Souzou Capital
- Series C, Feb 6, 2017, $3.4M — SBI Investment, Beyond Next Ventures, Keio Innovation Initiative
- Seed, Oct 15, 2015, $0.6M — Beyond Next Ventures
- Seed, Feb 1, 2015, $0.3M — Beyond Next Ventures

## Investors

- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Seed, Series C, Series D
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series C, Series D
- Keio Innovation Initiative (https://capitalatlas.ai/funds/keio-innovation-initiative) — Series C, Series D, Series E
- Dai-ichi Life Insurance — Series D, Series E, Series F
- Itochu — Series D
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series D
- ITOCHU Technology Ventures (https://capitalatlas.ai/funds/itochu-technology-ventures) — Series D, Series E, Series F
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series D, Series E
- Chibagin Capital (https://capitalatlas.ai/funds/chibagin-capital) — Series D
- Cyberdyne, Inc. — Series D
- Saison Ventures (https://capitalatlas.ai/funds/saison-ventures) — Series D
- Iwagin Jigyo Souzou Capital (https://capitalatlas.ai/funds/iwagin-jigyo-souzou-capital) — Series D, Series E
- Mori Trust — Series E
- Koshidaka Holdings — Series E, Series F
- INTAGE HOLDINGS Inc. — Series E
- Sumitomo Mitsui Trust Investment (https://capitalatlas.ai/funds/sumitomo-mitsui-trust-investment) — Series F
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series F
- Healthcare Innovation — Series F
- Saisei Ventures (https://capitalatlas.ai/funds/saisei-ventures) — Series F
- Shinsei Impact Investment (https://capitalatlas.ai/funds/shinsei-impact-investment) — Series F